Newly Diagnosed MM Patients Data Presented at ASH 2015.

All patients received Aspirin 325 mg/day VRd patients received HSV prophylaxis Durie B, ASH 2015 Abst 25 VRd Eight 21-day Cycles Rd Six 28-day Cycles Rd Maintenance Until PD, Toxicity or Withdrawal Lenalidomide 25 mg D Dex 40 mg D1, 8,15, 22 Randomization N = 525 Stratification: ISS (I, II, III) Intent to progression (yes/no) Bortezomib 1.3/mg 2 IV D 1, 4, 8, 11 Lenalidomide 25 mg/day D1-14 Dex 20 mg/day D1, 2, 4, 5, 8, 9, 11,12 Lenalidomide 25 mg/day D 1-21 Dexamethasone 40 mg D 1, 8, 15, 22 SWOG S0777 Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma SWOG S0777